NovoLet® Acceptance Study Within the Hospital Practise in Indonesia

Completed

• Conditions: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes
• Interventions: Drug: insulin human

• Registration Number: NCT01492205
• Lead Sponsor: Novo Nordisk A/S

Brief Summary

This study is conducted in Asia. The aim of this study is to evaluate the overall acceptance of healthcare professionals (nurses and doctors) to the NovoLet® system used in a hospital environment.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-09
• Primary Completion: 2006-06
• Study Completion: 2006-06
• Study First Submitted: 2011-12-12
• Study First Submitted QC: 2011-12-12
• Study First Posted: 2011-12-14
• Status Verified: 2016-10
• Last Update Submitted: 2016-10-13
• Last Update Posted: 2016-10-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 203

Inclusion Criteria

• Type 1 diabetes
• Type 2 diabetes
• Likely to be hospitalised and require insulin therapy

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Human insulin	insulin human	-

Primary Outcome Measures

Name	Time	Method
Overall acceptance of the NovoLet® system among healthcare professionals (nurses and doctors)

Secondary Outcome Measures

Name	Time	Method
Time taken for the healthcare professionals (nurses and doctors) to teach the patient
Incidence of adverse drug reactions

Trial Locations

Locations (1)

Novo Nordisk Investigational Site; 🇮🇩 Jakarta, Indonesia